Clinical Trials Logo
  1. Home
  2. HIV Infections
  3. NCT05983679
  4. Details
NCT05983679 Clinical Trial

Prevalence of Sexually Transmitted Infections (STIs) and Coinfections in the General Population

HIV Infections Clinical Trial

— PREMINF  

Official title:
Prevalence of Sexually Transmitted Infections (STIs) and Co-infections in the General Population

Clinical Trial Details — Status: Not yet recruiting

Administrative data
NCT number NCT05983679
Other study ID # PREMINF
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date December 4, 2024
Est. completion date September 4, 2026

Study information
Verified date April 2024
Source CerbaXpert
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

Prevalence of Sexually Transmitted Infections (STIs) and co-infections in the general population

Recruitment information / eligibility
Status Not yet recruiting
Enrollment 9000
Est. completion date September 4, 2026
Est. primary completion date September 4, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Subject, male or female, 18 years of age or older - Subject capable of understanding the purpose of the research having given their free and informed written consent - Subject presenting to the laboratory for a biological examination - Affiliated subject or beneficiary of a social security scheme Exclusion Criteria: - Protected subject: adult under guardianship, curatorship or other legal protection, deprived of liberty by judicial or administrative decision

Study Design

Related Conditions & MeSH terms

Intervention

Diagnostic Test:
• Blood sample
Blood sample

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
CerbaXpert

Outcome
Type Measure Description Time frame Safety issue
Primary The prevalence of each STI will be assessed by the participant's positive or negative status for each pathogen, determined by the following screening tests: HIV testing is based on finding antibodies to HIV-1 and HIV-2 and P24 antigen of the virus;
Hepatitis B screening is based on HBsAg (hepatitis B surface antigen) research;
Herpes screening is based on testing for antibodies to Herpes Simplex virus (HSV-1 and HSV-2);
Papilloma virus screening is based on the HPV-HR test from a smear on the cervix;
Chlamydia screening is based on a nucleic acid amplification (NAAT) test;
Gonorrhea screening is based on the identification of the bacteria on a urine sample or secretions from the vagina or cervix;
Screening for trichomoniasis is based on a molecular diagnosis that involves identifying the parasite's DNA from a genital or urinary sample;
The detection of syphilis is based on antibody research.		 3 years
See also
  Status Clinical Trial Phase
Completed NCT05454514 - Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS N/A
Completed NCT03760458 - The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age Phase 1/Phase 2
Completed NCT03067285 - A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study Phase 4
Completed NCT03141918 - Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS N/A
Recruiting NCT04579146 - Coronary Artery Disease (CAD) in Patients HIV-infected
Completed NCT06212531 - Papuan Indigenous Model of Male Circumcision N/A
Active, not recruiting NCT03256422 - Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients Phase 3
Completed NCT03256435 - Retention in PrEP Care for African American MSM in Mississippi N/A
Completed NCT00517803 - Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies N/A
Active, not recruiting NCT03572335 - Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
Completed NCT04165200 - Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV N/A
Recruiting NCT03854630 - Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection Phase 4
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A
Completed NCT02234882 - Study on Pharmacokinetics Phase 1
Completed NCT01618305 - Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission Phase 4
Recruiting NCT05043129 - Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
Not yet recruiting NCT05536466 - The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine N/A
Recruiting NCT04985760 - Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy Phase 1
Completed NCT05916989 - Stimulant Use and Methylation in HIV
Terminated NCT02116660 - Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) Phase 2